Navigation Links
First HeartAssist5® VAD Implant Performed in the U.S.
Date:3/10/2015

Chicago, Illinois (PRWEB) March 10, 2015

A patient at the University of Chicago Medicine was the first in the United States to be implanted with the HeartAssist5® Ventricular Assist Device (VAD) as part of an FDA clinical trial being conducted by Houston-based ReliantHeart, Inc.

The HeartAssist5® VAD is a small mechanical pump implanted to support left heart function when the left ventricle can no longer pump enough blood to sustain the body. The FDA Investigational Device Exemption (IDE) clinical trial in the U.S. will evaluate the safety and efficacy of 96 patients implanted with ReliantHeart’s HeartAssist5® VAD compared to 96 patients implanted with either a Thoratec HeartMate II® LVAD or HeartWare HVAD®, in providing left ventricular support while awaiting cardiac transplantation. The trial is expected to run through 2016.

“Some novel features in this device have the potential to improve patient outcomes,” said Valluvan Jeevanandam, MD, professor of surgery and section chief of cardiac surgery at the University of Chicago. “The pumping mechanism is designed to reduce the risk of blood clots and the built-in wireless monitors can alert the team early if blood flow issues develop.”

The HeartAssist5® VAD provides benefits not currently available with existing VAD technology such as a proprietary true-flow measurement system and the HeartAssistRemote™ Monitoring System, which continuously transmits patient data to expert clinicians 24 hours per day via vadlink.com. These optimized device features may allow for faster and more precise diagnosis of potential issues.

The HeartAssist5® is approved in Europe for patients awaiting a heart transplant and as a destination therapy for patients who are not candidates for cardiac transplantation.

About ReliantHeart Inc.
ReliantHeart Inc. is a leading innovator in mechanical circulatory support therapies for advanced stage heart failure. The company manufactures the HeartAssist5®, a next generation ventricular assist device (VAD) which has CE Mark approval for commercial sale in Europe. The HeartAssist5® is an implantable, electric pump designed for use in patients requiring ventricular support due to end stage heart failure and is the world’s only remotely monitored VAD. ReliantHeart is privately held and headquartered in Houston, Texas. For more information please visit http://www.reliantheart.com

Read the full story at http://www.prweb.com/releases/2015/02/prweb12538074.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups
2. Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico
3. SQI Diagnostics Reports First Quarter Financial Results
4. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015
5. SQI Diagnostics to Announce First Quarter 2015 Results
6. China Cord Blood Corporation to Report Third Quarter and First Nine Months of Fiscal 2015 Financial Results
7. Unchained Labs Has a Busy First Day! Raises $25 Million and Closes First Acquisition
8. Developers #HackMS at the First Ever Hackathon for Multiple Sclerosis
9. SPIE Photonics West 2015 opens with big first-day attendance
10. Events.com Integrates Engagement Management Technology, Captive Reach, Providing a Robust User Experience for Mobile-first Registration Platform
11. Origin Agritech Limited Reports Unaudited Financial Results For Three Months Ended December 31, 2014 and Announces its First United States Patent Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):